

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. **L04617**

2-14-00
First Named Inventor or Application Identifier

Scanlan et al.

Express Mail Label No. **EL024661754US**

Date of Deposit **February 11, 2000**

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

- | | |
|--|--|
| <p>1. <input checked="" type="checkbox"/> Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification [Total pages 29]
16 pages description
1 page abstract
12 pages claims
56 claims</p> <p>3. Drawing(s) (35 USC 113)
[Total sheets <u> </u>]
<input type="checkbox"/> Informal <input type="checkbox"/> Formal
[Total drawings <u> </u>]</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration [Total pages 3]
a. <input type="checkbox"/> Newly executed (original or copy)
b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
<i>[Note Box 5 below]</i></p> <p>i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>
Signed statement attached deleting
inventor(s) named in the prior application, see
37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input checked="" type="checkbox"/> Incorporation by Reference
(usable if Box 4b is checked)
The entire disclosure of the prior application,
from which a copy of the oath or declaration is
supplied under Box 4b, is considered as being
part of the disclosure of the accompanying
application and is hereby incorporated by
reference therein.</p> | <p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence
Submission (if applicable, all necessary)
a. <input checked="" type="checkbox"/> Computer Readable Copy (see "other" below)
b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)
c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p> |
|--|--|

ACCOMPANYING APPLICATION PARTS

- 8. Assignment Papers (cover sheet & documents(s))
- 9. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
- 10. English Translation of Document (if applicable)
- 11. Information Disclosure Copies of IDS
Statement (IDS)/PTO-1449 Citations
- 12. Preliminary Amendment
- 13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 14. Small Entity Statement filed in prior
Statement(s) application, Status still proper
and desired
- 15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. Other: Associate Power of Attorney; Letter requesting use of previous computer readable form; copy of computer disk label from previous case.

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: 08/948,705

Cancel in this application original claims 1-5, 7-36 and 41-56 of the prior application before calculating the filing fee.

Amend the specification by inserting before the first line the sentence:

This application is a divisional of application serial no. 08/948,705, filed October 10, 1997, entitled ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON CANCER, and now pending.

Express Mail Label No:
EL024661754US
Date of Deposit: 2-11-00

18. CORRESPONDENCE ADDRESS

Correspondence address below

ATTORNEY'S NAME	John R. Van Amsterdam, Reg. No. 40,212				
NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	<i>John R. Van Amsterdam</i>
DATE	FEBRUARY 11, 2000

Inventor or Identifier: Scanlan et al.

Serial No: Not yet assigned

Filed: Herewith

CHECK BOX, if applicable:

 DUPLICATEFor: ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED
WITH COLON CANCER AND METHODS FOR
DIAGNOSING AND TREATING COLON CANCER

Fee Calculation Sheet

CLAIMS	FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEES
	TOTAL CLAIMS (37 CFR 1.16(c))	14-20=	0 x	\$18	= \$0.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	2-3=	0 x	\$78	= \$0.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) +			\$	= \$0.00
				BASIC FEE (37 CFR 1.16(a))	\$ 690.00
				Total of above Calculations =	\$690.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				\$
				Assignment Recordation Fee (if any)	\$ 0.00
	Other Fees (e.g., Petition for Extension of Time), if any NOTE: Enter small-entity amount if applicable.				\$ 0.00
				TOTAL =	\$690.00

1. A check in the amount of \$690.00 is enclosed.

General Authorization to Charge Deposit Account and General Request for Extension of Time

2. a. If the filing of any paper in this application necessitates the payment of a fee under 37 CFR § X1.16 X1.17 or X1.18, and the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.
- b. The applicant hereby revokes any prior authorization to charge a fee due under 37 CFR § 1.16 1.17 or 1.18.
3. If the filing of any paper in this application necessitates an extension of time under 37 CFR § 1.136(a), the applicant hereby requests such extension of time. If the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617) 720-3500
Attorneys of Record

JC625 U.S. PTO
09/502945
02/11/00

